Feasibility and efficacy of lidocaine cream-mediated extracorporeal shock wave therapy for postherpetic neuralgia
SUN Fuguo1,2, YE Ling1, CHEN Lu1, LIU Hui1
1. Department of Pain Management,West China Hospital of Sichuan University,Chengdu 610000,China; 2. Department of Anesthesiology,Sichuan Provincial Corps Hospital of Chinese People's Armed Police Force,Leshan 614000,China
Abstract：Objective To evaluate the clinical feasibility and efficacy of lidocaine cream being used as a divergent extracorporeal shock wave therapy(ESWT) for postherpetic neuralgia. Methods Ninety patients with non-head and face postherpetic neuralgia were randomly divided into two groups using the block randomization method.The treatment group(n=45) received lidocaine cream-mediated ESWT while the control group(n=45) was treated with ultrasonic couplant-mediated ESWT.Both groups received medication,ESWT,pulsed radiofrequency and nerve block. The Visual Analogue Scale(VAS),hyperalgesia,Hamilton Depression Scale(HAMD),doses of opioids and pregabalin and adverse reactions were observed in both groups for 12 weeks. Results Pain score comparison: Immediately after treatment and 2 weeks after treatment, the Visual Analogue Scale (VAS) of the treatment group was 1.96±0.77 and 2.25±0.89 respectively, compared with 2.97±0.79 and 3.40±0.81 in the control group. The doses of oxycodone and pregabalin were lower in the treatment group than in the control group.There were no complications related to ESWT in either group. Conclusions Our data suggests that lidocaine cream-mediated ESWT is effective and safe for PHN patients, which can be used as a supplementary treatment of PHN in grassroots hospitals.
Werner R N, Nikkels A F, Marinovic B, et al. European consensus-based (S2k) guideline on the management of herpes zoster-guided by the european dermatology forum (EDF) in cooperation with the european academy of dermatology and venereology (EADV), Part 1: Diagnosis[J]. J Eur Acad Dermatol Venereol, 2017, 31(1):9-19.
[2]
Yang F, Yu S, Fan B, et al. The epidemiology of herpes zoster and postherpetic neuralgia in China: results from a cross-sectional study[J]. Pain Ther, 2019, 8(2):249-259.
[3]
Lin C S, Lin Y C, Lao H C, et al. Interventional treatments for postherpetic neuralgia: a systematic review[J]. Pain Physician, 2019, 22(3):209-228.
[4]
Walewicz K, Taradaj J. The effectiveness of radial extracorporeal shock wave therapy in patients with chronic low back pain: a prospective, randomized, single-blinded pilot study[J]. Clin Interv Aging, 2019, 14:1859-1869.
[5]
De Lima Morais T M, Meyer P F, De Vasconcellos L S, et al. Effects of the extracorporeal shock wave therapy on the skin: an experimental study[J]. Lasers Med Sci, 2019, 34(2):389-396.
Hausner T, Nogradi A. The use of shock waves in peripheral nerve regeneration: new perspectives?[J]. Int Rev Neurobiol, 2013, 109:85-98.
[12]
Derry S, Wiffen P J, Moore R A, et al. Topical lidocaine for neuropathic pain in adults[J]. Cochrane Database Syst Rev, 2014, 7: 10958.
[13]
Casale R, Mattia C. Building a diagnostic algorithm on localized neuropathic pain (LNP) and targeted topical treatment: focus on 5% lidocaine-medicated plaster[J]. Ther Clin Risk Manag, 2014, 10:259-268.
[14]
Baron R,Allegri M,lanes G, et al.The 5% lidocaine-medicated plaster: its inclusion in international treatment guidelines for treating localized neuropathic pain, and clinical evidence supporting its Use[J]. Pain Ther, 2016, 5(2):149-169.
[15]
Clere F, Delorme M C, George B, et al. 5% lidocaine medicated plaster in elderly patients with postherpetic neuralgia: results of a compassionate use programme in France[J]. Drugs Aging, 2011, 28(9):693-702.
[16]
Lopez L M, Rivera A L, Fernandez F, et al. Shock wave-induced permeabilization of mammalian cells[J]. Phys Life Rev, 2018, 26-27:1-38.
[17]
Luh J J, Huang W T, Lin K H, et al. Effects of extracorporeal shock wave-mediated transdermal local anesthetic drug delivery on rat caudal nerves[J]. Ultrasound Med Biol, 2018, 44(1):214-222.
Johnson R W, Wasner G, Saddier P, et al. Postherpetic neuralgia: epidemiology, pathophysiology and management[J]. Expert Rev Neurother, 2007, 7(11):1581-1595.
[20]
Truini A, Garcia L, Cruccu G. Reappraising neuropathic pain in humans--how symptoms help disclose mechanisms[J]. Nat Rev Neurol, 2013, 9(10):572-582.
[21]
Wasner G, Kleinert A, Binder A, et al. Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin[J]. J Neurol, 2005, 252(6):677-686.
[22]
Corallo F, Salvo S, Floridia D, et al. Assessment of spinal cord stimulation and radiofrequency: chronic pain and psychological impact[J]. Medicine (Baltimore), 2020, 99(3):e18633.
[23]
Kasper S, Brasser M, Schweizer E, et al. How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies[J]. Eur Neuropsychopharmacol, 2014, 24(1):125-132.
[24]
Onakpoya I J, Lee J J, Thomas E T, et al. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials[J]. BMJ Open, 2019, 9(1):e023600.
2021, Vol. 32 
